Reslizumab

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 490 publications

Real-world disease burden, patient journey and treatment patterns in eosinophilic granulomatosis with polyangiitis in Europe and the USA.

Real-world disease burden, patient journey and treatment patterns in eosinophilic granulomatosis with polyangiitis in Europe and the USA.

Journal: EULAR rheumatology open

Published: August 01, 2026

Characteristics of severe asthma patients with biologic treatment in the Swedish National Airway Register.

Characteristics of severe asthma patients with biologic treatment in the Swedish National Airway Register.

Journal: European clinical respiratory journal

Published: July 28, 2026

Modern approaches in asthma management: Revolutionizing severe asthma treatment with biologics.

Modern approaches in asthma management: Revolutionizing severe asthma treatment with biologics.

Journal: JPMA. The Journal of the Pakistan Medical Association

Published: June 27, 2026

Therapeutic Efficacy of Anti-Interleukin-5 Monoclonal Antibodies in Kimura Disease: A Systematic Review.

Therapeutic Efficacy of Anti-Interleukin-5 Monoclonal Antibodies in Kimura Disease: A Systematic Review.

Journal: Cureus

Published: June 12, 2026

A Narrative Review of Biologic Therapies for Type 2 Inflammation in Severe Asthma and Eosinophilic Chronic Obstructive Pulmonary Disease (COPD): Mechanisms, Efficacy, and Safety.

A Narrative Review of Biologic Therapies for Type 2 Inflammation in Severe Asthma and Eosinophilic Chronic Obstructive Pulmonary Disease (COPD): Mechanisms, Efficacy, and Safety.

Journal: Cureus

Published: May 30, 2026

New perspectives in the treatment of chronic eosinophilic pneumonia in the era of targeted therapies.

New perspectives in the treatment of chronic eosinophilic pneumonia in the era of targeted therapies.

Journal: Frontiers in immunology

Published: May 28, 2026

Biologic therapies targeting type 2 inflammation in NSAID-exacerbated respiratory disease.

Biologic therapies targeting type 2 inflammation in NSAID-exacerbated respiratory disease.

Journal: Frontiers in immunology

Published: May 25, 2026

Documentation of biological treatment in asthma

Documentation of biological treatment in asthma

Journal: Pneumologie (Stuttgart, Germany)

Published: May 18, 2026

Safety of anti-IL-5 compounds for the treatment of eosinophilic asthma with a focus on special populations.

Safety of anti-IL-5 compounds for the treatment of eosinophilic asthma with a focus on special populations.

Journal: Expert opinion on drug safety

Published: May 11, 2026

Efficacy and Safety of IL-4Rα and IL-5/IL-5R Targeted Biologic Therapies in Type 2 Inflammatory Airway Diseases: A Systematic Review and Meta-Analysis.

Efficacy and Safety of IL-4Rα and IL-5/IL-5R Targeted Biologic Therapies in Type 2 Inflammatory Airway Diseases: A Systematic Review and Meta-Analysis.

Journal: Journal of clinical medicine

Published: May 11, 2026

The Use of Biomarkers to Justify the Choice of the Proper Biologic Agent for the Treatment of Chronic Rhinosinusitis with Nasal Polyps: A Systematic Review.

The Use of Biomarkers to Justify the Choice of the Proper Biologic Agent for the Treatment of Chronic Rhinosinusitis with Nasal Polyps: A Systematic Review.

Journal: Medicina (Kaunas, Lithuania)

Published: May 10, 2026

Biological functions and clinical efficacy of IL-5/IL-5Rα-targeted therapies across eosinophilia-associated diseases.

Biological functions and clinical efficacy of IL-5/IL-5Rα-targeted therapies across eosinophilia-associated diseases.

Journal: Frontiers in immunology

Published: May 07, 2026

Showing 1-12 of 490

Last Updated: 09/26/2026